Supplementary Figure 2 Anti-PD-L1 (avelumab) enhances CD8 activation and decreases CD4 to a greater extent than commercially available anti-PD-L1 blocking.

Slides:

Advertisements

Similar presentations

Volume 94, Issue 2, Pages (March 2014)

Advertisements

Volume 17, Issue 9, Pages (September 2015)

Figure 1. CD11b+CD33+CD14+HLA-DR−/lo myeloid-derived suppressor cell expansion by human immunodeficiency virus.

Supplementary Figure 3 Antigen-specific responses are enhanced by stimulation in an in vitro stimulation (IVS) assay, as well as with stimulation using.

Supplementary Figure 1 Supplementary Figure 1: ROR agonists increase the expression of a luciferase reporter driven by Gal4-ROR. In HEK293T cells, Gal4-ROR

Cytokine Production and Antigen Recognition by Human Mucosal Homing Conjunctival Effector Memory CD8+ T Cells Invest. Ophthalmol. Vis. Sci ;55(12):

Volume 116, Issue 5, Pages (May 1999)

% of Suppression a-TGFb (ug/ml) Tr/Tresp 1:1 1:4

Molecular Therapy - Methods & Clinical Development

Supplementary Figure S1

Supplementary Table 1: primer sequences

“Analyses of Pre-therapy Peripheral Immunoscore and Response to

Volume 122, Issue 5, Pages (May 2002)

Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators by Rikke Bæk Sørensen, Sine Reker Hadrup, Inge Marie Svane, Mads Christian.

A B C D CD4+ CD8+ Control Isotype Ab Anti-TNFa Ab Control Isotype Ab

Volume 116, Issue 5, Pages (May 1999)

CMV-, EBV- and ADV-Specific T Cell Immunity: Screening and Monitoring of Potential Third-Party Donors to Improve Post-Transplantation Outcome Cinja Sukdolak,

Maintenance of HCV-specific T-cell responses in antibody-deficient patients a decade after early therapy by Nasser Semmo, Michaela Lucas, George Krashias,

A B A B C Supplementary Fig. 8 Supplementary Fig. 9

Interleukin (IL)-1β-producing cells in peripheral blood mononuclear cells (PBMCs). Interleukin (IL)-1β-producing cells in peripheral blood mononuclear.

Volume 31, Issue 5, Pages (November 2009)

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

Volume 137, Issue 3, Pages e7 (September 2009)

CD300a is expressed on human B cells, modulates BCR-mediated signaling, and its expression is down-regulated in HIV infection by Rodolfo Silva, Susan Moir,

Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.

Volume 137, Issue 2, Pages (August 2009)

Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.

Cytomegalovirus-specific T cells are primed early after cord blood transplant but fail to control virus in vivo by Suzanne M. McGoldrick, Marie E. Bleakley,

Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses by Cagan Gurer, Till.

FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.

CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors Xupeng.

Myeloid-Derived Suppressor Cells in Psoriasis Are an Expanded Population Exhibiting Diverse T-Cell–Suppressor Mechanisms Lauren Y. Cao, Jin-Sung Chung,

Volume 147, Issue 1, Pages e7 (July 2014)

Volume 143, Issue 6, Pages e4 (December 2012)

Volume 38, Issue 2, Pages (February 2013)

IL-22 Increases the Innate Immunity of Tissues

Jack F Bukowski, Craig T Morita, Michael B Brenner Immunity

Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation

Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice Simone Thomas,

TSLP Directly Interacts with Skin-Homing Th2 Cells Highly Expressing its Receptor to Enhance IL-4 Production in Atopic Dermatitis Kazuki Tatsuno, Toshiharu.

Volume 138, Issue 2, Pages e4 (February 2010)

The absence of ADCC by nivolumab in vitro.

Jack F Bukowski, Craig T Morita, Michael B Brenner Immunity

Volume 31, Issue 5, Pages (November 2009)

Volume 33, Issue 1, Pages (July 2010)

a b Supplementary Figure 1

Increased, but Functionally Impaired, CD14+ HLA-DR–/low Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells David C. Soler,

Volume 134, Issue 7, Pages e2 (June 2008)

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

Volume 117, Issue 6, Pages (December 1999)

A comparison of gene transfer and antigen-loaded dendritic cells for the generation of CD4+ and CD8+ cytomegalovirus-specific T cells in HLA-A2+ and HLA-A2−

Melanoma Inhibitor of Apoptosis Protein (ML-IAP) Specific Cytotoxic T Lymphocytes Cross-React with an Epitope from the Auto-Antigen SS56 Rikke Bæk Sørensen,

MHC-Dependent and -Independent Activation of Human Nickel-Specific CD8+ Cytotoxic T Cells from Allergic Donors1 Corinne Moulon, Doris Wild, Hans Ulrich.

Dysregulation of Lymphocyte Interleukin-12 Receptor Expression in Sézary Syndrome Mohamed H. Zaki, Ryan B. Shane, Yuemei Geng, Louise C. Showe, Suzanne.

Volume 7, Issue 2, Pages (August 1997)

A.K.I. Kuroki, Masayuki Iyoda, Takanori Shibata, Tetsuzo Sugisaki

Volume 8, Issue 2, Pages (August 2003)

Volume 8, Issue 7, Pages (March 1998)

Harald Renz, MD, Chaya Brodie, PhD, Katherine Bradley, BS, Donald Y. M

PD-1 blockade enhances T-cell function.

Defining antigen-specific responses with human MHC class II tetramers

Volume 4, Issue 6, Pages (June 1996)

Detection of Antigen-Specific B Cells in Patients with Pemphigus Vulgaris by Enzyme- Linked Immunospot Assay: Requirement of T Cell Collaboration for Autoantibody.

The number of islet antigen–specific T cells is reduced in CT-treated RIP-LCMV-GP mice. The number of islet antigen–specific T cells is reduced in CT-treated.

Volume 67, Issue 6, Pages (June 2005)

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

Immunologic and pharmacokinetic studies.

Pretreatment of donor T cells with a c-Rel antagonist does not impair GVT activity. Pretreatment of donor T cells with a c-Rel antagonist does not impair.

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection Sara Ferrando-Martinez, Kelly Huang, Angie.

Volume 138, Issue 2, Pages e4 (February 2010)

Presentation transcript:

Supplementary Figure 2 Anti-PD-L1 (avelumab) enhances CD8 activation and decreases CD4 to a greater extent than commercially available anti-PD-L1 blocking antibodies a. HD#1 HD#2 HD#3 CD8 DP CD4 Ratio CD8 DP/CD4 Isotype Anti-PD-L1 Anti- PD-L1 EMD Serono (Avelumab, IgG1) 2 21 55 23 0.04 0.9 3 12 59 22 0.05 0.55 15 77 27 0.6 eBioscience (clone MIH1, IgG1) 57 45 0.3 4 60 58 0.07 9 68 0.06 0.13 Biolegend (clone 29E.2A3, IgG2bk) 5 56 50 0.1 10 66 0.15 r= -0.70 p= 0.0433 EMD Serono (Avelumab, IgG1) Biolgend (clone 29E.2A3, IgG2bk) eBioscience (clone MIH1, IgG1) b. Anti-PD-L1 (avelumab) enhances CD8+ T-cell activation and decreases CD4+ lymphocyte number to a greater extent than commercially available anti-PD-L1 blocking antibodies. PBMCs from 3 healthy donors were stimulated as in Supplementary Figure 3a with CEFT or HLA, and treated with 20 ug/mL of EMD Serono anti-PD-L1 (avelumab, IgG1), eBioscience anti-PD-L1 (clone MIH1, IgG1), Biolegend anti-PD-L1 (clone 29E.2A3, IgG2bk), or the appropriate isotype controls. PBMCs were harvested on day 12 of the in vitro stimulation assay and analyzed by flow cytometry for the frequency of PBMCs that were CD8+CD107a+IFNγ+ (double positive, DP), or CD4+, as well as the ratio of CD8+ DP:CD4+. (a) Bold font highlights differences that are >50% between PBMCs that were stimulated with CEFT peptide pool and treated with anti-PD-L1 blocking antibodies compared to cultures stimulated with CEFT and treated with the appropriate isotype control. (b) Correlation between CD4+ T cells and CD8+CD107a+IFNγ+ T cells in CEFT-stimulated PBMCs treated with anti-PD-L1 blocking antibodies. Values were calculated as a percentage of PBMCs and analyzed using the Spearman correlation. Abbreviations: CEFT, cytomegalovirus, Epstein–Barr virus, influenza, and tetanus toxin; HLA, human leukocyte antigen; PBMCs, peripheral blood mononuclear cells.